Review article · 2024 · Open access
Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis
PLoS ONE, 19(7), e0306548 · Published 31 July 2024 · DOI 10.1371/journal.pone.0306548
In brief
“Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis” is a 2024 review article by Konstantinos Ouranos and 6 co-authors, published in PLoS ONE. OpenAlex counts 20 citations as of 19 November 2026, which puts it in the top 2% of works published in 2024 by citations. It is open access under a CC BY licence: the full text is free to read at PLoS ONE.
- Citations
- 20
- Most cited in
- 2025 (12)
- Field-weighted impact
- 1.13
- References
- 75
- Authors
- 7
Abstract
Patients with rheumatoid arthritis (RA) who receive immunosuppressive medications have a heightened risk of infection. The goal of our study was to calculate the pooled cumulative incidence and risk of infection in patients with RA treated with Janus kinase inhibitors (JAKi). The PubMed and EMBASE databases were queried for randomized controlled trials comparing patients with RA treated with JAKi (upadacitinib, baricitinib, tofacitinib, peficitinib, or filgotinib), defined as the treatment group, compared with control subjects, defined as participants receiving placebo or treatment regimen that was similar to that of participants in the treatment group, with the exception of JAKi. The primary study endpoint was the relative risk (RR) of any-grade and severe infection. The secondary endpoints were RR and cumulative incidence of opportunistic infections, herpes zoster, and pneumonia. The Stata v17 software was used for all data analysis. Results showed that treatment with baricitinib was associated with an increased risk of any-grade (RR 1.34; 95% CI: 1.19-1.52) and opportunistic (RR 2.69; 95% CI: 1.22-5.94) infection, whereas treatment with filgotinib (RR 1.21; 95% CI: 1.05-1.39), peficitinib (RR 1.40; 95% CI: 1.05-1.86) and upadacitinib (RR 1.30; 95% CI: 1.09-1.56) was associated with increased risk of any-grade infection only. Analysis based on type of infection showed a pooled cumulative incidence of 32.44% for any-grade infections, 2.02% for severe infections, 1.74% for opportunistic infections, 1.56% for herpes zoster, and 0.49% for pneumonia in patients treated with any JAKi during the follow-up period. Treatment with specific JAKi in patients with RA is associated with an increased risk of any-grade and opportunistic infections but not severe infection. Close clinical monitoring of patients with RA treated with JAKi is required to establish the long-term infection risk profile of these agents.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Ouranos, K., Avila, D. V., Mylona, E. K., Vassilopoulos, A., Vassilopoulos, S., Shehadeh, F., & Mylonakis, E. E. (2024). Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis. PLoS ONE, 19(7), e0306548. https://doi.org/10.1371/journal.pone.0306548
MLA 9
Ouranos, Konstantinos, et al. “Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis.” PLoS ONE, vol. 19, no. 7, 2024, p. e0306548. https://doi.org/10.1371/journal.pone.0306548.
Chicago
Ouranos, Konstantinos, Diana V. Avila, Evangelia K. Mylona, Athanasios Vassilopoulos, Stephanos Vassilopoulos, Fadi Shehadeh, and Eleftherios E Mylonakis. 2024. “Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis.” PLoS ONE 19 (7): e0306548. https://doi.org/10.1371/journal.pone.0306548.
Harvard
Ouranos, K. et al. (2024) ‘Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis’, PLoS ONE, 19(7), p. e0306548. doi:10.1371/journal.pone.0306548.
IEEE
K. Ouranos et al., “Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis,” PLoS ONE, vol. 19, no. 7, p. e0306548, 2024, doi: 10.1371/journal.pone.0306548.
BibTeX
@article{ouranos2024cumulative,
title = {{Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis}},
author = {Ouranos, Konstantinos and Avila, Diana V. and Mylona, Evangelia K. and Vassilopoulos, Athanasios and Vassilopoulos, Stephanos and Shehadeh, Fadi and Mylonakis, Eleftherios E},
journal = {PLoS ONE},
year = {2024},
volume = {19},
number = {7},
pages = {e0306548},
doi = {10.1371/journal.pone.0306548},
url = {https://doi.org/10.1371/journal.pone.0306548}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- rheumatoid arthritis
- JAK inhibitors
- infection risk
- opportunistic infections
- herpes zoster
- pneumonia
- baricitinib
- upadacitinib
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Ouranos, K., Avila, D. V., Mylona, E. K., Vassilopoulos, A., Vassilopoulos, S., Shehadeh, F., & Mylonakis, E. E. (2024). Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis. PLoS ONE, 19(7), e0306548. https://doi.org/10.1371/journal.pone.0306548
How many times has this paper been cited?
20 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PLoS ONE: sign in and open the full text from this page.
Who wrote this paper?
Konstantinos Ouranos, Diana V. Avila, Evangelia K. Mylona, Athanasios Vassilopoulos, Stephanos Vassilopoulos, Fadi Shehadeh, Eleftherios E Mylonakis.
What is the DOI of this paper?
10.1371/journal.pone.0306548, permanently at https://doi.org/10.1371/journal.pone.0306548. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.